The current financial score of Cogent Biosciences Inc is 6.80. Its financial status is robust, and its operating efficiency is low.
The current valuation score of Cogent Biosciences Inc is 8.61. Its current P/E ratio is -15.10, which is -86.54% below the recent high of -2.03 and -43.42% above the recent low of -21.65.
The current earnings forecast score of Cogent Biosciences Inc is 8.83. The average price target is 55.20, with a high of 60.00 and a low of 45.00.
The current price momentum score of Cogent Biosciences Inc is 3.81. Currently, the stock price is trading between the resistance level at 36.40 and the support level at 30.12, making it suitable for range-bound swing trading.
The current institutional shareholding score of Cogent Biosciences Inc is 10.00. The latest institutional shareholding proportion is 102.81%, representing a quarter-over-quarter increase of 14.34%. The largest institutional shareholder is James Simons, holding a total of 996.17K shares, representing 0.05% of shares outstanding, with 2198.18% increase in holdings.
The current risk assessment score of Cogent Biosciences Inc is 6.26. The company's beta value is 0.35. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.